WS
ADVM

Wedbush Securities’s Adverum Biotechnologies ADVM Stock Holding History

Wedbush Securities’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,750
Closed -$47K – 840
2017
Q1 		$47K Hold
1,750
– – 0.01% 804
2016
Q4 		$51K Buy
+1,750
New +$57.2K 0.01% 777

Other funds holding ADVM

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities's ADVM Position: Q2 2017 in Review

Wedbush Securities sold out of Adverum Biotechnologies (ADVM) in Q2 2017, closing a stake of 1,750 shares — an estimated $47K sold.

Wedbush Securities first reported a position in ADVM in Q4 2016 and held it in 2 quarters. The position peaked at $51K in Q4 2016. 63 funds tracked by Wall St. Rank hold ADVM as of Q2 2017.

  • Wedbush Securities reported no remaining Adverum Biotechnologies position as of Q2 2017 after selling out during the quarter.
  • Wedbush Securities sold 1,750 Adverum Biotechnologies shares in Q2 2017, an estimated $47K.
  • Wedbush Securities first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 2 quarters.
  • Wedbush Securities's Adverum Biotechnologies position peaked at $51K in Q4 2016.
  • 63 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2017.

Based on Wedbush Securities's 13F filing for Q2 2017, filed 2 Aug 2017.